Pharmaceuticals

Primary Myelofibrosis Market Forecast 2026–2030 Presenting Long-Term Industry Insights

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Primary Myelofibrosis Market Grow Between 2026 And 2030?

The market size for primary myelofibrosis has demonstrated substantial growth in recent years. It is projected to expand from $0.84 billion in 2025 to $0.9 billion in 2026, at a compound annual growth rate (CAGR) of 6.4%. The expansion observed historically can be attributed to several factors including limited available therapeutic options, instances of delayed diagnosis and misdiagnosis, insufficient disease awareness, a dependence on conventional treatments, and a restricted patient population.

The primary myelofibrosis market is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach $1.14 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.2%. This projected increase can be attributed to several factors, including the emergence of innovative targeted treatments, a rise in clinical trial engagement, progress in genetic and molecular diagnostic methods, increased funding for hematology research, and the expanding implementation of personalized medicine. Key developments anticipated during this timeframe involve heightened awareness and earlier detection of primary myelofibrosis, an expansion of targeted therapies and individualized treatment strategies, broader use of sophisticated diagnostic instruments, an increase in clinical studies and research endeavors, and a greater emphasis on patient support initiatives and disease management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24669&type=smp

Which Strong Drivers Are Impacting The Primary Myelofibrosis Market Growth?

The growing incidence of myelofibrosis is poised to stimulate the expansion of the primary myelofibrosis market in the future. Myelofibrosis is defined as an uncommon form of bone marrow cancer which interferes with the body’s standard blood cell production, causing significant scarring within the bone marrow, and manifesting as severe anemia, weakness, tiredness, and an enlarged spleen. The heightened prevalence of myelofibrosis largely stems from an aging population, given that the ailment predominantly impacts those above 60 years old, with extended life expectancies contributing to an elevated count of identified instances. An escalating occurrence of myelofibrosis facilitates advancements in the management of primary myelofibrosis by stimulating research, refining early detection, broadening available treatments, and encouraging superior clinical protocols and specialized services. For example, in November 2024, the National Institute for Health and Care Excellence, an independent executive non-departmental public body situated in the UK, reported that myelofibrosis affects 3.2 per 100,000 people in the UK and has an incidence rate of 0.6 per 100,000. Consequently, the growing incidence of myelofibrosis is fueling the expansion of the primary myelofibrosis market.

What Are The Key Segment Divisions In The Primary Myelofibrosis Market Segment Structure?

The primary myelofibrosis market covered in this report is segmented –

1) By Type: Spinocerebellar Primary Myelofibrosiss, Primary Myelofibrosis-Telangiectasia, Episodic Primary Myelofibrosis, Other Types

2) By Services: Treatment, Diagnosis

3) By Dosage Forms: Solid, Liquids, Other Dosage Forms

4) By Age: Adult, Child, Geriatric

5) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis, Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis, Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations

2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis, Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis, Ocular Telangiectasia-Associated Myelofibrosis

3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes, Periodic Cytopenia With Fibrosis Flare, Cyclical Myelofibrosis In Autoimmune Disorders

4) By Other Types: Familial Primary Myelofibrosis, Idiopathic Myelofibrosis, Therapy-Related Primary Myelofibrosis, Juvenile Primary Myelofibrosis

Which Trends Are Guiding The Direction Of The Primary Myelofibrosis Market?

Leading companies within the primary myelofibrosis market are prioritizing the development of innovative products, such as Janus kinase 2 inhibiting tablets, to enhance symptom management and slow disease progression. Janus kinase 2 (JAK2) inhibiting tablets are oral medications that block the activity of the JAK2 enzyme, which plays a role in the abnormal signaling pathways leading to excessive blood cell production in primary myelofibrosis. These tablets help reduce spleen size, alleviate symptoms like fatigue and bone pain, and decelerate the disease’s advancement. For example, in March 2025, GlaxoSmithKline Korea (GSK Korea) Ltd., a Korea-based pharmaceutical and biotechnology company, launched Omjjara (momelotinib), a new treatment for myelofibrosis. This medication is approved by South Korea’s Ministry of Food and Drug Safety and is intended for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who also experience moderate to severe anemia. Omjjara is an oral medication that inhibits Janus kinases (JAK1 and JAK2) and activin A receptor type 1 (ACVR1), proving effective in addressing symptoms such as anemia, enlarged spleen, and fatigue. Its approval is backed by clinical trial data that demonstrated significant improvements in anemia, spleen size, and overall symptoms compared to existing treatments.

Which Organizations Are Engaged In The Primary Myelofibrosis Market?

Major companies operating in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.

Get The Full Primary Myelofibrosis Market Report:

https://www.thebusinessresearchcompany.com/report/primary-myelofibrosis-global-market-report

Which Region Is The Leading Market For The Primary Myelofibrosis Market?

North America was the largest region in the primary myelofibrosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary myelofibrosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Primary Myelofibrosis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/primary-myelofibrosis-global-market-report

Browse Through More Reports Similar to the Global Primary Myelofibrosis Market 2026, By The Business Research Company

Myelodysplastic Syndrome Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-drugs-global-market-report

Myeloproliferative Disorders Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

Thrombectomy Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/thrombectomy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795